NatWest Markets Strategy & Sales

China Data: Q1 Will Test The Lower Limit
03 February 2020 06:51


Authors

Contributors
{{contributor-span-repeater}}

If you wish to discuss the content of this article further, please contact your usual sales person. Reminder, clients of Natwest Markets NV should reach out to their relevant NV sales person.

  

  • China’s manufacturing PMIs in January were in line with expectations and only marginally lower, but did not capture the impact from the latest coronavirus outbreak. Real activities and PMI data is set to worsen in the next few months as most economic activities were suddenly halted after the authorities locked down Chinese cities to prevent the rapid spread of virus.
  • We think the coronavirus outbreak will likely be a temporary shock to China’s growth and we remain cautiously optimistic that China’s longer term growth momentum will likely be stable if the authorities decisively step-up counter-cyclical policies in the near term to offset the negative impact.
  • As Chinese financial market re-opens from a longer than usual Chinese New Year holiday, the PBoC moved swiftly to inject a net CNY150bn liquidity in open market operations and lowered both 7-day and 14-day reverse repo rates by 10bps to 2.40% and 2.55% to stabilise financial market sentiment.
  • China’s growth momentum may face greater downward pressure in the near term and the authorities will likely prioritise support growth again in the upcoming National People’s Congress (probably in early March). We think both fiscal and monetary easing policies will be stronger to ensure growth momentum stabilises into H2.

Chinese markets re-opened today with the Shanghai Composite Index down by 9% and USDCNY spot trading above the key level of 7.00 after a longer than usual Chinese New Year holiday. The new coronavirus outbreak forced Chinese authorities to extend the holiday by one week day, and also led to a travel lockdown in several cities to prevent rapid spread of the virus. Prior to market open, the authorities have pledged firm support to the financial markets in the near term. The PBoC announced a net CNY 150bn liquidity injection via open market operations by 7-day and 14-day reverse repos and has lowered both 7-day and 14-day reverse repo rates by 10bps to 2.40% and 2.55% respectively. The 10bps rate cut in reverse repos was unexpected, and it increases the chance of lowering 1Y and 5Y Loan Prime Rate (LPR) in the upcoming announcement on 20 February. We think the PBoC will likely to continue support the banking system with ample liquidity to help commercial banks tide through the temporary liquidity crunch.

China’s manufacturing PMI data has shown some stability after the US-China Phase I deal greatly reduced near term risks of escalation. Official manufacturing PMI slowed marginally by 0.2 percentage points to 50.0 and was in line with market consensus. Caixin manufacturing PMI also came in line with expectations at 51.1, down marginally from 51.5 previously.  Business confidence improved marginally prior to the virus outbreak as corporates turned optimistic about both domestic and external demand into 2020. However, the stability may be short-lived as the new virus situation forced China to lock-down several cities and halted almost all economic activities during the Chinese New Year to prevent rapid spread of the disease. We expect China’s real activities data and PMI data to plunge in the next few months and that will weigh on the full year real GDP growth.

Drawing parallel to the SARS epidemic in 2003, we think the negative shock to China’s real GDP growth will likely be drastic but temporary. During SARS outbreak in 2003, China’s real GDP went down by 2 percentage points from 11.1% in Q1 ‘03 to 9.1% in Q2 ’03, but it quickly rebounded to 10.0% in Q3 ’03 and maintained high growth level for the remaining year. Unlike 2003, China’s now relies more on consumption rather than investment as the government has imposed strict deleveraging policies to prevent excessive debt accumulation by the local governments’ since 2018. Therefore the sudden halt in economic activities – especially the consumer sector such as tourism, box offices, transportation and services sectors – will likely have a bigger impact on Q1 GDP growth compared to 2003.

The impact on the manufacturing sector and employment will depend largely on when migrant workers return to the cities. Chinese New Year is typically the season when the manufacturing sector production and activities usually slow as migrant workers leave the factories. As a result of the outbreak of virus, this year most migration back to the cities has been delayed, causing some disruption to production activity. The impact is still uncertain and will depend on how the virus situation evolves. Based on the central government’s briefing, companies will likely resume production as early as this week, which may cause less negative shock to the overall growth momentum.

We expect the authorities to use the traditional lever of infrastructure sector investments more forcefully in 2020 as the economy faces more downside pressures. Even before the virus outbreak, the National Development and Reforms Commission (NDRC) has accelerated approvals and implementations of major infrastructure projects to offset the downside pressures from the lack of corporate investments and slowing consumption.

Despite the negative shock to near term growth momentum, we think the market does not need to be overly pessimistic about China’s longer term growth outlook due to the following reasons:

  1. The PBoC moved swiftly to cut rates by 10bps showed the authorities’ determination to support growth.

The PBoC’s rate cut today increases the chances of Loan Prime Rate (LPR) cut in February, which is not what we previously expected. We think the rate cuts today signal stronger and more decisive support to stabilise the financial market sentiment in the short term. We now expect a 5-10 bps LPR cut in February.

The upcoming National People’s Congress (NPC), which usually takes place in early March, will be an important time window for the market to confirm China’s pro-growth policy bias. As China is set to achieve a few medium term growth targets in 2020 such as doubling 2010 GDP by 2020 and fulfil its 13th Five Year Plan, we think the government will still tilt towards stabilising growth with stronger countercyclical easing policies in the next few quarters.

  1. Earlier easing policies are set to have some positive impact on the economy, and the authorities may step up decisively with stronger countercyclical fiscal and monetary easing policies to offset the negative impact on growth in the short term.

China’s credit impulse has picked up in recent months as the PBoC extended more credit to the real economy. We think the gradually stronger credit support will likely have some positive impact on the economic growth momentum as activities and demand picks up. We expect the credit impulse to rebound a little further into 2020 to around 5.0% from 1.9% as of December 2019, providing more support to the expected increase in credit demand.

In conclusion, we think the virus outbreak will likely be a temporary shock and we will watch closely as the situation evolves. If the virus situation could stabilise by Q1, we expect the growth momentum to resume into H2 with more countercyclical easing policies in place and recovering sentiment. We think if the domestic situation on coronavirus could stabilise by the end of Q1 and economic activities rebounds sharply with stronger easing policies, China’s real GDP may slow to around 5.0% yoy in Q1 and recovers to around 6.0% for the remaining quarters which will put the full year GDP growth at around 5.7% to meet its goals of doubling 2010 GDP by 2020.

Chart 1:Credit Impulse and Manufacturing PMI

Source: CEIC,NatWest Markets


Chart 2: Infrastructure Projects Pipeline and Investments

Source: NDRC, Bloomberg,NatWest Markets




  

  

  

  

  

  

Please click here to find all of NatWest Markets’ Strategy and Sales commentary/ideas. 

You can also find out more about our electronic offering and credentials for Rates here and for FX here.


This is Non-Independent Research, as defined by the Financial Conduct Authority. Not intended for Retail Client distribution. This material should be regarded as a marketing communication and may have been produced in conjunction with the NatWest Markets Plc trading desks that trade as principal in the instruments mentioned herein. All data is accurate as of the report date, unless otherwise specified.

This communication has been prepared by NatWest Markets Plc, and should be regarded as a Marketing Communication, for which the relevant competent authority is the UK Financial Conduct Authority.

Please follow the link for the following information https://www.natwestmarkets.com/natwest-markets/regulation/mar-disclosures.html:

  • MAR Disclaimer
  • Conflicts of Interest statement
  • Glossary of definitions
  • Historic Trade ideas log





All data is accurate as of the report date, unless otherwise specified.

 

This communication has been prepared by NatWest Markets Plc, NatWest Markets N.V. (and/or any branches) or an affiliated entity (“NatWest Markets”), and should be regarded as a Marketing Communication, for which the relevant competent authority is the UK Financial Conduct Authority (for NatWest Markets Plc) and the Autoriteit Financiële Markten (for NatWest Markets N.V.).

 

Please follow the link for the following information https://www.natwest.com/corporates/support/regulatory-information/market-abuse-regulation-mar-disclosures.html:

 

MAR Disclaimer

Conflicts of Interest statement

Glossary of definitions

Historic Trade ideas log

 

This material is a Marketing Communication and has not been prepared in accordance with the legal and regulatory requirements designed to promote the independence of investment research and may have been produced in conjunction with the NatWest Markets trading desks that trade as principal in the instruments mentioned herein. This commentary is therefore not independent from the proprietary interests of NatWest Markets, which may conflict with your interests. Opinions expressed may differ from the opinions expressed by other business units of NatWest Markets. The remuneration of the author(s) is not directly tied to any transactions performed, or trading fees received, by any entity of the NatWest Group, for example, through the use of commission-based remuneration.

 

This material includes references to securities and related derivatives that the firm's trading desk may make a market or provide liquidity in, and in which it is likely as principal to have a long or short position at any time, including possibly a position that was accumulated on the basis of this analysis material prior to its dissemination. Trading desks may also have or take positions inconsistent with this material. This material may have been made available to other clients of NatWest Markets before it has been made available to you and is not subject to any prohibition on dealing ahead of its dissemination. This document has been prepared for information purposes only, does not constitute an analysis of all potentially material issues and is subject to change at any time without prior notice. NatWest Markets does not undertake to update you of such changes. It is indicative only and is not binding. Other than as indicated, this document has been prepared on the basis of publicly available information believed to be reliable but no representation, warranty, undertaking or assurance of any kind, express or implied, is made as to the adequacy, accuracy, completeness or reasonableness of this material, nor does NatWest Markets accept any obligation to any recipient to update, correct or determine the reasonableness of such material or assumptions contained herein. NatWest Markets and each of its respective affiliates accepts no liability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise) arising from the use of this material or reliance on the information contained herein. However this shall not restrict, exclude or limit any duty or liability to any person under any applicable laws or regulations of any jurisdiction which may not lawfully be disclaimed. The opinions, commentaries, projections, forecasts, assumptions, estimates, derived valuations and target price(s) or other statements contained in this communication (the “Views”) are valid as at the indicated date and/or time and are subject to change at any time without prior notice. NatWest Markets does not undertake to update you of such changes. Views expressed herein are not intended to be, and should not be viewed as advice or as a personal recommendation. The Views may not be objective or independent of the interests of the authors or other NatWest Markets trading desks, who may be active participants in the markets, investments or strategies referred to in this material. NatWest Markets will not act and has not acted as your legal, tax, regulatory, accounting or investment adviser; nor does NatWest Markets owe any fiduciary duties to you in connection with this and/or any related transaction and no reliance may be placed on NatWest Markets for investment advice or recommendations of any sort. You should make your own independent evaluation of the relevance and adequacy of the information contained in this document and make such other investigations as you deem necessary, including obtaining independent financial advice, before participating in any transaction in respect of the securities referred to in this document. This document is not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The information contained herein is proprietary to NatWest Markets and is being provided to selected recipients and may not be given (in whole or in part) or otherwise distributed to any other third party without the prior written consent of NatWest Markets.

 

NatWest Markets and its respective affiliates, connected companies, employees or clients may have an interest in financial instruments of the type described in this document and/or in related financial instruments giving rise to potential conflicts of interest which may impact the performance of such financial instruments. Such interests may include, but are not limited to, (a) dealing in, trading, holding or acting as market-maker or liquidity provider in such financial instruments and any reference obligations; (b) entering into hedging strategies on behalf of issuer clients and their affiliates, investor clients or for itself or its affiliates and connected companies; and (c) providing banking, credit and other financial services to any company or issuer of securities or financial instruments referred to herein. NatWest Markets and its affiliates, connected companies, employees or clients may at any time acquire, hold or dispose or long or short positions (including hedging and trading positions) which may impact the performance of a financial instrument.

 

In the U.S., this Marketing Communication is intended for distribution only to major institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act 1934 (excluding documents produced by our affiliates within the U.S. which are subject to the following disclaimer https://www.agilemarkets.com/api/ds/v1/disclaimer/publication/2756 ). Any U.S. recipient wanting further information or to effect any transaction related to this trade idea must contact NatWest Markets Securities Inc., 600 Washington Boulevard, Stamford, CT, USA. Telephone: +1 203 897 2700.

 

Where communicated in Singapore, this communication may be deemed an advertisement. This advertisement has not been reviewed by the Monetary Authority of Singapore.

 

NatWest Markets Plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority and is provisionally registered as a swap dealer with the United States Commodity Futures Commission. NatWest Markets N.V. is incorporated with limited liability in the Netherlands, authorised by De Nederlandsche Bank and regulated by De Nederlandsche Bank and the Autoriteit Financiële Markten. It has its seat at Amsterdam, the Netherlands, and is registered in the Commercial Register under number 33002587. Registered Office: Claude Debussylaan 94, Amsterdam, The Netherlands. Branch Reg No. in England BR001029. Agency agreements exist between different members of NatWest Group. Securities business in the United States is conducted through NatWest Markets Securities Inc., a FINRA registered broker-dealer ( http://www.finra.org ), a SIPC member ( www.sipc.org ) and a wholly owned indirect subsidiary of NatWest Markets Plc. NatWest Markets Securities Inc. is authorised by NatWest Markets Plc to act as its agent for certain kinds of its activities.

 

For further information relating to materials provided by NatWest Markets, please view our Agile Markets Terms and Conditions

 

Copyright © NatWest Markets Plc. All rights reserved.